Benzimidazole carbamate residues in milk: Detection by Surface Plasmon Resonance-biosensor, using a modified QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe) method for extraction by Keegan, Jemma et al.
TITLE: Benzimidazole carbamate residues in milk: Detection by Surface Plasmon Resonance-biosensor,
using a modified QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe)
method for extraction.
AUTHORS: Jemma Keegan, Michelle Whelan, Martin Danaher, Steven Crooks, Regina Sayers, Aniello
Anastasio, Christopher Elliott, David Brandon, Ambrose Furey, Richard O’Kennedy
This article is provided by the author(s) and Teagasc T-Stór in accordance with publisher policies.
Please cite the published version.
The correct citation is available in the T-Stór record for this article.
NOTICE: This is the author’s version of a work that was accepted for publication in
Analytica Chimica Acta. Changes resulting from the publishing process, such as peer
review, editing, corrections, structural formatting, and other quality control mechanisms
may not be reflected in this document. Changes may have been made to this work since it
was submitted for publication. A definitive version was subsequently published in
Analytica Chimica Acta (2009), 654(2), 111-119. DOI: 10.1016/j.aca.2009.09.028This item is made available to you under the Creative Commons Attribution-Non
commercial-No Derivatives 3.0 License.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Benzimidazole carbamate residues in milk: Detection by SPR
biosensor, using a modified QuEChERS method for extraction
Jemma Keegana,b, Michelle Whelana,c, Martin Danahera, Steven Crooksd, Regina Sayerse, Aniello
Anastasiof, Christopher Elliottg, David Brandonh, Ambrose Fureyc, Richard O’Kennedyb
aAshtown Food Research Centre, Teagasc, Ashtown, Dublin 15, Ireland
bSchool of Biotechnology and National Centre for Sensor Research, D ublin City University, Dublin
9, Ireland
c Cork Institute of Technology, Bishopstown, Cork, Ireland
dVeterinary Sciences Division, Agri-Food & Biosciences Institute, Belfast, Northern Ireland
eTeagasc Dairy Production Research Centre, Moorepark, Fermoy, Co . Cork, Ireland
fFaculty of Veterinary Medicine, Federico II University, Naples, Italy
gInstitute of Agri-Food and Land, School of Biological Sciences, Queen’s University Belfast,
Belfast, Northern Ireland
hWestern Regional Research Center, US Department of Agriculture, Agricultural Research Service,
Albany, California, USA
Abstract
A surface plasmon resonance (SPR) biosensor screening assay was developed and validated to
detect 11 benzimidazole carbamate (BZT) veterinary drug residues in milk. The polyclonal
antibody used was raised in sheep against a methyl 5 (6)-[(carboxypentyl)-thio]-2-benzimidazole
carbamate protein conjugate. A sample preparation procedure was developed using a modified
QuEChERS method. BZT residues were extracted from milk using liquid extraction/partition with a
dispersive solid phase extraction clean-up step. The assay was validated in accordance with the
performance criteria described in 2002/657/EC. The limit of detection of the assay was calculated
from the analysis of 20 known negative milk samples to be 2.7 µg kg-1. The detection capability
(CCβ) of the assay was determined to be 5 µg kg-1 for 11 benzimidazole residues and the mean
recovery of analytes was in the range 81 to 116%. A comparison was made between the SPR-
biosensor and UPLC-MS/MS analyses of milk samples (n = 26) taken from cows treated different
benzimidazole products, demonstrating the SPR-biosensor assay to be fit for purpose.
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581. Introduction
Benzimidazole anthelmintic drugs are widely used in veterinary medicine for the treatment of
helminth infections in food-producing animals. These infections result in reductions in milk yields
[1] and weight gain [2, 3]. In the EU, 11 benzimidazoles and pro-benzimidazoles are approved for
treatment of food-producing animals giving rise to 20 potential residues. These include the
benzimidazole carbamates, albendazole (ABZ), albendazole sulphoxide (ABZ-SO), oxfendazole
(FBZ-SO), fenbendazole (FBZ), mebendazole (MBZ), oxibendazole (OXI), flubendazole (FLU),
thiabendazole (TBZ) (a thiazole benzimidazole), triclabendazole (TCB) and the pro-benzimidazoles
(febantel and netobimin). However ABZ and FBZ related drugs are the only ones approved in the
treatment of lactating animals and have maximum residue limits (MRLs) in bovine and ovine milk
(Table 1) under Commission 2377/90/EC [4]. The main concerns over the presence of
benzimidazole residues in milk are related to their teratogenic and embryotoxic properties [5, 6].
The requirement to monitor benzimidazole residues in milk is supported by pharmacokinetic studies
which have shown that benzimidazole residues are excreted in the milk and non-compliant levels of
residues may occur if withdrawal periods are not followed [7, 8].
Danaher et al. reviewed the analysis of benzimidazole residues in food, highlighting the analytical
challenges caused by their extensive metabolism in food producing animals [9]. Recently a number
of groups have reported methods for isolating multiple veterinary residues from food using
QuEChERS, the so called Quick, Easy, Cheap, Effective, Rugged and Safe method widely used in
pesticide residue analysis [10-12]. QuEChERS offers several advantages over most conventional
techniques because it does not require glassware or ancillary equipment (e.g. vacuum manifolds),
uses low volumes of solvent, generates little solvent waste and provides high recovery of analytes
[12]. HPLC coupled to UV and/or fluorescence detection is the most widely used technique to
measure benzimidazole residues in milk [13, 14] However HPLC based methods often require
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58more intensive sample preparation, particularly when monitoring for low levels of benzimidazole
residues [15, 16]. More recently, groups have developed LC-MS/MS methods to detect residues in
food that require less complicated clean-up steps [17, 18]. Immunoassay-based detection systems
have been developed by other groups as an alternative to chemical assays with improvements in
sensitivity, selectivity and require simpler sample preparation in comparison to chemical based
assays [19-23]. The SPR-biosensor was first presented as an alternative immunochemical detection
system in veterinary drug residue analysis in 1995 [24]. More recently, several SPR-biosensor
assays have been developed to detect veterinary drug residues in milk [25-28]. SPR-biosensor
assays employ label-free detection and have proven to be versatile, robust and capable of producing
rapid and reliable results with minimum sample preparation [25]. Johnsson et al. developed an SPR
biosensor assay method capable of detecting benzimidazole residues in bovine serum samples using
a simple extraction [29] but no SPR-biosensor method for detecting these substances in food
matrices has yet to be reported in the literature.
This research describes the development of a sensitive SPR-biosensor assay to detect trace levels of
11 out of 14 major benzimidazole carbamate residues in milk combined with a modified
QuEChERS method for extraction. The polyclonal antibody does not cross-react to residues of
triclabendazole or thiabendazole drugs. The suitability of the assay was demonstrated through its
application to samples taken at different withdrawal periods from cows treated with different
benzimidazole products and comparing results with UPLC-MS/MS. The method was validated
according to the 2002/657/EC guidelines as required for EU monitoring programs [30]. The factors
investigated included recovery, repeatability and analytical limits, including the limit of detection
and detection capabilities (CCβ) of the method.
2. Materials and methods
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58.1 Chemicals and reagents
M5 sensor chips (research grade), NHS (100 mM N-hydroxysuccinimide in water), EDC (400
M 1 -ethyl-3 -(3 -dimethylaminopropyl)-carbodiimide hydrochloride in water), 1 M ethanolamine
nd HBS-EP buffer (10 mM HEPES pH 7.4 with 0.05 M NaCl, 3.4 mM EDTA and 0.005% P20
v/v) were all obtained from GE Healthcare (Uppsala, Sweden). Sodium hydroxide (NaOH), HPLC
rade water, pesticide grade acetonitrile (ACN), pesticide grade dimethylsulphoxide (DMSO) and
ethanol were supplied by BDH/VWR international Ltd. (Poole, England, UK). Ethylenediamine
99%, v/v), Jeffamine (4- [(4-aminophenyl)methyl]aniline, C13H14N2), dimethylformamide, ABZ, MBZ,
BZ and FBZ were supplied by Sigma Aldrich (Steinheim, Germany). OXI, FBZ-SO and FLU
ere purchased from QMX laboratories (Thaxted, UK). Amino-mebendazole (MBZ-NH2), hydroxy-
ebendazole (MBZ-OH), amino-flubendazole (FLU-NH2) and hydroxy-flubendazole (FLU-OH)
ere received as a gift from Janssen pharmaceuticals (Belgium). ABZ-SO, albendazole sulphone
ABZ-SO2), albendazole amino sulphone (ABZ-NH2-SO2), fenbendazole sulphone (FBZSO2), 5-
ydroxy-thiabendazole (5-OH-TBZ), TCB, triclabendazole sulphoxide (TCB-SO),
riclabendazole sulphone (TCB-SO2) and keto-triclabendazole (keto-TCB) were purchased from
itega laboratories (Berlin, Germany). ABZ-D3, ABZ-SO-D3, ABZ-SO2-D3, FBZ-D5, FBZ-SO-
5, FBZ-SO2-D5, MBZ-D3, MBZ-OH-D3, FLU-D3 and OXI-D7 were from Witega laboratories
Berlin, Germany). ABZ-NH2-SO2-D2 was from Quchem (Belfast, Northern Ireland, UK). Primary
tandard stock solutions for each benzimidazole were prepared in DMSO or methanol depending on
olubility. Working standard solutions were prepared by diluting the primary standard solutions in
ethanol. Deuterated internal standards were prepared at concentrations of 1 mg mL-1 in DMSO or
ethanol-d. A working standard solution (2 µg mL-1) was prepared by diluting the primary stock
nternal standard solution in methanol-d.
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58olypropylene centrifuge tubes with screw caps (50 mL) containing 4 g magnesium sulphate
MgSO4) and 1 g NaCl were supplied by United Chemical Technologies (Bristol, PA, USA).
olypropylene tubes (50 mL) containing 1.5 g magnesium sulphate (MgSO4) and 0.5 g C18 were
urchased from Biotage (Uppsala, Sweden). Whatman syringe Filter units (polytetrafluoroethylene
PTFE), 0.2 µm) were purchased from Fisher scientific (Dublin, Ireland).
.2 Milk samples
.2.1 Negative control samples
resh bovine milk samples were collected from milk tanks on farms and those found to be free of
enzimidazole residues by UPLC-MS/MS (limit of quantitation of 1 µg kg-1) were used as negative
ontrols. The UPLC-MS/MS method was capable of detecting the all of the major metabolites of
BZ, FBZ, MBZ and FLU drugs.
.2.2 Incurred milk samples
ilk from cows treated with ABZ and FBZ products
wo cows were treated with Panacur SC 10% (7.5 mg FBZ kg-1 b.w. (bodyweight)) and Endospec
0% (7.5 mg ABZ kg-1 b.w.) oral suspension, respectively. Pooled quarter milk samples were taken
rom each animal immediately prior to dosing and again at subsequent morning and evening
ilkings for 11 milkings, with a minimum milking interval of 9 hours. The final milk sample was
aken 135 hours post-treatment.
ilk from cows treated with febantel product
our samples were taken from a cow treated with Rintal 1.9% (1000 mg Febantel in feed) at 7, 24,
1 and 168 h post-treatment.
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58.3 SPR-Biosensor assay
.3.1 Modified QuEChERS sample preparation
ilk samples (12 g) were extracted using a slurry containing ACN:MgSO4:NaCl (12:4:1, v/w/w) by
haking vigorously by hand (1 min). The samples were centrifuged (3500g, 10 min, -5°C) and the
upernatant was transferred to a tube containing C18 sorbent (500 mg) and MgSO4 (1.5 g). The
ubes were subsequently shaken (1 min) and centrifuged (3500g, 10 min, -5°C). The ACN layer
7.5 mL) was transferred to Pyrex® tubes and evaporated to dryness at 50°C, under nitrogen.
xtracts were reconstituted in DMSO (2.5 mL), vortexed (2 min) and sonicated (10 min). Extracts
2.5 mL) were diluted in water (2.5 mL), vortex mixed (1 min) and filtered (0.22 µm) into
ppendorf® tubes. The sample extract was diluted (1:4, v/v) in HBS-EP buffer and vortex mixed
20 s) prior to biosensor analysis.
.3.2 SPR-Biosensor Chip preparation
CM5 chip was allowed to equilibrate to room temperature and HBS-EP buffer (50 µL) was added
o the chip surface and incubated (10 min). The buffer was removed and 50 mM NHS:200 mM
DC (1:1, v/v, 40 µL) was added to the chip surface and incubated (20 min) to activate the surface.
his solution was removed and 1 M ethylenediamine pH 8.5 (50 µL) was allowed to incubate (1 h).
he remaining unreacted groups on the chip surface were deactivated by addition of 1 M
thanolamine-HCl (50 µL) and allowed to react (20 min). Methyl 5(6)-[(carboxypentyl)-thio]-2-
enzimidazolecarbamate (2 mg) [19] was dissolved in DMF (450 µL) and mixed with a solution
ontaining NHS (2 mg) and EDC (5 mg) in 10 mM sodium acetate buffer pH 4.5 (450 µL) and
llowed to react on the chip surface (2 h) at room temperature. The chip was washed with HPLC
rade water and dried under a stream of nitrogen gas. The immobilised chip was stored in a
esiccated container (4°C).
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58.3.3 SPR-Biosensor analytical cycle
he optical biosensor used was a Biacore Q (GE Healthcare, Uppsala Sweden) with Biacore® Q
ontrol software version 3.0. BIAevaluation software version 3.0.1 was used for data handling.
tudies were conducted at 25ºC. The polyclonal antibody (raised in sheep against a methyl 5(6)-
carboxypentyl)-thio]-2-benzimidazolecarbamate derivative (CMB)) [29] was received from the
eterinary Sciences Division, Agri-Food and Biosciences Institute, Belfast, Northern Ireland. An
ntibody dilution of 1/1200, v/v, was found to give satisfactory results under the assay conditions.
ntibody and milk extract were mixed (1:3, v/v) and passed over the immobilised surface at 10 µL
in-1 (1 min). Regeneration of the chip was carried out by sequential injection of 25 mM HCl (15
L) followed by 180 mM NaOH (20 µL) across the chip surface at 25 µL min-1. The binding of
ntibody to the chip surface was measured as the change in surface plasmon resonance (SPR) signal
etween two report points, before (10 s) and after (30 s) each injection. A competitive
mmunoassay assay format was used to detect inhibition of antibody binding to the chip surface.
PR signal was expressed in arbitrary resonance units (RU).
.4 UPLC-MS/MS assay
.4.1 UPLC-MS/MS Sample preparation
amples were analysed by the method developed by De Ruyck et al [31]. Milk samples (5 g) were
piked with internal standard solution and let stand for 30 min. Samples were adjusted to alkaline
onditions by addition of 10M NaOH (100 μL). Ethyl acetate (15 mL) was added to samples,
hich were shaken (60 oscillations min-1, 5 min). Samples were centrifuged (2500g, 10 min). The
upernatant layer was transferred to a polypropylene centrifuge tube (15 mL), DMSO (0.25 mL)
as added and the ethyl acetate was evaporated under nitrogen at 5 0°C. Samples were filtered
hrough 0.2 μm PTFE filters and 5 μL was injected onto the UPLC-MS/MS system.
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58.4.2 UPLC-MS/MS detection conditions
he UPLC-MS/MS system consisted of a Waters Acquity® separations module and a Quattro
remier XE equipped with ESI interface (Waters, Milford, MA, USA). The separation was carried
ut on a stainless steel Waters Acquity® analytical column (100 x 2.1 mm), packed with HSS T3
18, 1.8 µm and Waters Acquity UPLC Column In-Line Filter Unit containing a 0.2 µm stainless
teel replacement filter (all from Waters). The pump was operated at a flow rate of 0.6 mL min-1
nd column temperature was maintained at 60oC. The chromatographic separation was achieved
sing a binary gradient comprised of – Mobile phase A, 0.01% acetic acid in water:ACN (900:100
/v) and Mobile phase B, 5mM Ammonium formate in MeOH:ACN (750:250, v/v) pumped at a
low rate of 0.6 mL min-1. Mobile phase was prepared daily and filtered using 0.2 µm filter
embrane and degassed in an ultrasonic bath for 15 min. The gradient profile was as a follows (1) 0
o 0.5 min, 100%A, (2) 5 min, 50%A, (3) 7 min, 10%A, (4) 8.5 min, 10%A, (5) 8.51 min, 0% A, (6)
.5 min, 0%A, (7) 9.51 min, 100%A, (8) 13 min 100%A. The UPLC-MS/MS system was
ontrolled by Masslynx software and the results were processed by TargetLynx Software.
S analyses were performed by atmospheric pressure electrospray ionisation in positive ion mode.
he capillary voltage was set at 3 kV. The source and desolvation temperatures were set at 150 and
50°C, respectively. The nitrogen desolvation and cone gases were set at 1000 and 50 L h-1,
espectively. The MS/MS conditions were optimised by tuning the cone voltage and collision
nergy for each analyte by infusing a 1000 ng mL-1 standard solution of each analyte individually
nd monitoring the two most abundant fragment ions produced from the molecular ion. Data were
cquired in multiple reaction monitoring (MRM) as outlined in Table 2.
.5 Calibration
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582.5.1 Biosensor calibration
Calibration curves were prepared in matrix by fortifying negative milk samples at concentrations of
0, 2.5, 5, 10, 15, 25 and 50 μg kg-1 with an ABZ-SO2 standard prior to extraction. BIAevaluation
software was used to prepare inhibition assay standard curves based on a four-parametric fit. The
concentration in test samples was read directly from the calibration curve.
2.5.2 UPLC-MS/MS calibration
Two approaches were adopted for measurement of benzimidazole residues in samples. In the first
approach for measuring low levels of benzimidazoles, calibration curves were prepared by
fortifying negative milk samples at concentrations of 1, 2, 5, 10, 25, 50, 100 and 200 μg kg-1, and
incubated for 30 min prior to extraction. Samples were also fortified with the internal standard
mixture at this time. In the second method for measuring high levels of benzimidazoles, calibration
curves were prepared by fortifying negative milk samples at concentrations of 10, 20, 50, 100, 250,
500, 1000, 2000 μg kg-1 and incubated for 30 min prior to extraction. A lower volume of ethyl
acetate extract (1.5 mL) was carried through to analysis to ensure linearity of curves.
3. Results and discussion
3.1 Antibody inhibition studies
The antibody cross-reactivity was investigated by analysing standards prepared in buffer by SPR-
biosensor assay. The antibody was shown to have significant affinity to 11 benzimidazole residues
in the following order of affinity FBZ-SO, FBZ-SO2 > ABZ-SO > ABZ, MBZ > ABZ-SO2 > MBZ-
OH > FLU > OXI > FBZ, FLU-OH (Table 3). The antibody did not show affinity to TCB, keto-
TCB, TCB-SO, TCB-SO2, TBZ, 5-OH-TBZ, MBZ-NH2, FLU-NH2 or ABZ-NH2-SO2 residues at a
concentration of 100 µg kg-1. A more detailed investigation of the antibody cross-reactivity was
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58carried out by preparing inhibition curves in buffer at concentrations from 0 to 30 ng mL-1
(equivalent to 0 to 50 µg kg-1) for the 11 different analytes. The 11 benzimidazole residues studied
showed significant cross-reactivity with IC50 values of typically <6.6 ng mL-1 (Table 3). A second
study was carried out using the modified QuEChERS extraction in milk calibration curves over the
range 0 to 50 µg kg-1. IC50 values in matrix typically ranged from 11 to 18 µg kg-1 for OFZ to
FBZ, respectively (Table 3). Extracted milk calibration curves for the 11 analytes are shown in
Fig. 1.
3.2 Development of sample preparation procedure
The extraction of benzimidazole residues was initially evaluated using conventional solvent
extraction with ACN and liquid-liquid extraction with ethyl acetate at different pHs. ACN was
found to give the best recovery of benzimidazoles and did not require pH manipulation. However,
lower recovery was observed for ABZ and FBZ compared to other benzimidazole metabolites. An
extraction method based on QuEChERS, which was recently applied to isolate benzimidazole
residues was also investigated but initially gave low recovery [14]. A spiking experiment was
performed and the results identified that recovery losses with the QuEChERS method occurred due
to the inability to resuspend residues. It was proposed that losses were either due to adsorption of
residues onto glassware or, more likely, tight binding of residues by milk proteins. A further
QuEChERS experiment was designed to evaluate the effect of alternative resuspension solvents
such as MeOH:water (50:50, v/v) and various concentrations of DMSO in water on the recovery of
ABZ, FBZ, FLU, MBZ and OXI. Recovery was found to be <60% for ABZ, FBZ, FLU, MBZ and
OXI residues when reconstituted in MeOH:water (50:50, v/v) (Fig. 2). The percentage recovery for
all 11 benzimidazole residues was found to be acceptable (≥69%) using DMSO:water (50:50, v/v, 5
mL). In order to allow the detection of benzimidazoles to less <5 μg kg-1 in milk, the sample
weight was increased to 12 g and extracts were diluted (1:4, v/v) with HBS-EP buffer. A working
antibody dilution (1/1200,v/v), flow rate (10 µL min-1), contact time (1 min) and antibody:extract
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58ix ratio (1:3, v/v) were optimised to give a response approximately equal to 380 RU (b0) for
enzimidazole-negative milk samples. The SPR-biosensor assay regeneration conditions were based
n conditions developed for this antibody by Johnnson et al [29].
.3 Method validation
qualitative approach was used to determine the performance factor CCβ (detection capability) as
escribed in 2002/657/EC. Firstly, the limit of detection (LOD) of the assay was determined to be
.7 µg kg-1 by measuring the mean response for 20 different negative bovine milk samples (371.4
U) and subtracting three standard deviations (3 x 12.5 RU). Secondly, in order to determine CCβ
alues, samples (n = 20 for each analyte) were spiked at a concentration above the LOD. An
rbitrary concentration of 5 µg kg-1 was selected because this level is equivalent of detection levels
hat can be achieved by HPLC based assays and it was considered that assay under study could
outinely measure this concentration level. In routine application, where several possible
enzimidazole residues may be detected in a naturally positive sample, the assay is able to detect
ummed metabolites at ≥2.7 µg kg-1 (comparable to UPLC-MS/MS). CCβ is the concentration at
hich a substance can be identified as positive (>LOD) with a statistical certainty of 1 – β.
amples (n = 20) were fortified at a level of 5 µg kg-1 for each analyte and assayed. If 19 of the 20
ortified samples were identified as positive, CCβ was to be determined to be 5 µg kg-1 (5%
robability of false negative result). If 20 or ≤1 8 samples were identified as positive, CCβ was
etermined to be less than or greater than 5 µg kg-1, respectively. The results for the CCβ
alidations for each analyte are shown in Table 4. The CCβ value for nine analytes was found to
e <5 µg kg-1. CCβ values for FLU-OH and MBZ were found to be equal to 5 µg kg-1, in each case
ne sample was not identified as positive. The two false negative samples gave measured results of
.65 and 2.05 µg kg-1, respectively. However, the method satisfies the false negative rate (≤5%) as
equired by 2002/657/EC.
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58The repeatability of the assay was evaluated by analysing fortified milk samples (5 µg kg-1) with the
11 analytes on five separate days (Table 5). Results showed that recovery (81-116%) and inter-
assay coefficients of variation (typically <30%). Calibration curves for each day are presented in
Fig. 3. A calibration curve prepared in HBS-EP buffer is also presented in Fig. 3, which
demonstrates the low rate of non-specific binding and high extraction efficiency of the method.
3.4 Application of assay to incurred milk samples
The suitability of the SPR-biosensor assay was evaluated by analysing incurred milk samples and
comparing results with UPLC-MS/MS. In the first study, a bovine animal was treated with Panacur
SC 10% (active ingredient FBZ) and milk samples were taken from prior to treatment to 135 h post
treatment in accordance with the daily milking routine. Milk samples were independently analysed
by two different analysts by SPR biosensor and UPLC-MS/MS. FBZ marker residues were
detectable in samples by UPLC-MS/MS for 72 h post-treatment (Table 6) with residues below the
MRL at 63 h post-treatment at a level of 7.5 µg kg-1. A typical UPLC-MS/MS trace from incurred
milk containing the three major FBZ residues is shown in Fig. 4a. Results from SPR biosensor
analysis showed that residues were also detected in milk samples and correctly identified as positive
(i.e. >LOD of 2.7 µg kg-1) for 72 h post-treatment. The results of this study showed that the SPR-
biosensor results were typically higher than UPLC-MS/MS at the 63 and 72 h sampling periods. It
is likely that the antibody used in the assay also measures other FBZ metabolites, which have no
available FBZ standards. The method was also applied to milk samples from a cow treated with
Rintal 1.9% (active ingredient FBZ pro-drug – Febantel). The samples in this study were collected
at 7, 24, 31 and 168 h post-treatment. FBZ marker residues were detected by UPLC-MS/MS at
high levels for the first three samples but were non-detectable at 168 h post-treatment. The SPR-
biosensor results agreed well with the UPLC-MS/MS results for these samples.
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58The ability of the SPR-biosensor assay to detect ABZ residues prior to the study was of concern
because of the absence of antibody cross-reactivity to ABZ-NH2-SO2. To verify the suitability of
the assay a bovine animal was treated with Endospec 10% (active ingredient ABZ) and milk
samples were taken from prior to treatment to 135 h post treatment in accordance with the daily
milking routine. A typical UPLC-M S/MS trace from an incurred milk found to contain the four
major ABZ residues is shown in Fig. 4b. ABZ marker residues were detectable by UPLC-MS/MS
for 87 h post-treatment but had depleted to below the MRL of 100 µg kg-1 at 39 h post-treatment
(Table 7). The SPR-biosensor assay was capable of detecting ABZ residues in milk samples up to
63 h post-treatment where residues were detected at a level of 4.3 µg kg-1.
4. Conclusions
This SPR-biosensor assay is suitable for use as a rapid screening method for the detection of 11
benzimidazole residues in milk. An extensive validation of the assay was carried out for 11
benzimidazole metabolites. The CCβ for benzimidazole residues was determined to be 5 µg kg-1,
which is equivalent to the existing chemical assay. The false negative rate for the assay was ≤5%.
Using the methodology presented in this article, it is possible to extract and analyse 20 samples
within a single working day. Any suspect positive samples can be confirmed by UPLC-MS/MS
analysis.
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7. Table 1
Table 1 Maximum residue limits (MRLs) for benzimidazole residues in milk.
Drug Marker residue (possible metabolites) MRL(µgkg-1) Animal species
TBZ TBZ and 5-OH-TBZ aNone Caprine
FLU FLU, FLU-NH2and FLU-OH aNone bNot permitted
OXI OXI aNone bNot permitted
TCB Sum of extractable residues that may be oxidised aNone bNot permitted
to ketotriclabendazole
MBZ MBZ, MBZ-OH and MBZ-NH2 and MBZ aNone bNot permitted
aNo MRL has been set for this drug in milk
bDrug is not permitted for use in animals producing milk for human consumption
Sum of ABZ-SO, ABZ-SO2, ABZ-SO and ABZ-
NH2-SO2, expressed as ABZ
Sum of residues that may be extracted as oxidised
to FBZ-SO2
100 Bovine and ovine
10 Bovine and ovine
ABZ,
ABZ-SO
Netobimin
FBZ
Febantel
FBZ-SO
7. Table 2
Table 2 MS/MS parameters for benzimidazole analytes and internal standards
Compound Transition
(m/z)
Dwell time
(s)
Cone
Energy (V)
Collision
energy (eV)
ABZ-NH2-SO2 240.08> 133.15 0.050 40 27
240.08> 198.1 0.050 40 20
ABZ-NH2-SO2-D3 242> 133 0.050 40 28
MBZ-NH2 238.1 > 105.09 0.025 50 24
238.1 > 133.05 0.025 50 34
FLU-NH2 256.06> 123.05 0.010 45 26
256.06> 95.1 0.010 45 34
ABZ-SO 282.24> 159.06 0.005 27 35
282.24> 240.1 0.005 27 15
ABZ-SO-D3 285.28> 243.02 0.005 41 13
ABZ-SO2 298.1 > 159.08 0.005 42 35
298.1 > 266.2 0.005 42 20
MBZ-OH 298.25> 160.05 0.005 38 33
298.25> 266.15 0.005 38 22
ABZ-SO2-D3 301 > 158.95 0.005 40 38
MBZ-OH-D3 301.15> 160.05 0.005 36 32
OFZ 316.1> 159.05 0.020 35 30
316.1 > 191.09 0.020 35 24
FBZ-SO2-D5 321.04> 158.95 0.020 30 32
OXI 249.9 > 175.9 0.010 35 26
249.9 > 218 0.010 35 18
OXI-D7 257.15 > 177.05 0.005 32 28
ABZ 266.07 > 191.03 0.015 33 32
266.07 > 234 0.015 33 13
ABZ-D3 269.12> 233.85 0.015 35 19
MBZ 296.14 > 105.05 0.010 35 32
296.14 > 264.1 0.010 35 18
MBZ-D3 299.15 > 105.05 0.005 39 33
FLU 313.80 > 123 0.005 40 35
313.80 > 282 0.005 40 24
FLU-OH 316.2 > 125.1 0.05 40 33
316.2 > 160.05 0.05 40 35
FLU-D3 317.15 > 123 0.005 40 36
FBZ-SO2 331.9 > 158.9 0.005 35 36
331.9 > 300 0.005 35 21
FBZ-SO2-D5 337.06> 305.0 0.005 45 23
TCB-NH2 328 > 166.95 0.005 48 57
FBZ 300.01 > 159.01 0.005 35 24
300.01 > 268.01 0.005 35 23
FBZ-D5 305.01 > 273.01 0.005 28 15
7. Table 3
Table 3 Cross-reactivity profile of benzimidazole carbamates drugs to polyclonal
carboxy-albendazole antibody (S48) in HBS-EP buffer and in bovine milk
Buffer Milk
Analyte
aIC50 (ng mL-1) bCR50 (%)
cIC50
(µg kg-1)
dCR50 (%)
ABZ 4.5 98 13.3 95
ABZ-SO 4.4 100 12.7 100
ABZ-SO2 4.8 93 14.2 90
FBZ 6.6 67 17.3 73
FBZ-SO 4.0 110 11.5 111
FBZ-SO2 4.0 110 15.3 84
MBZ 4.5 98 12.3 103
MBZ-OH 5.0 88 13.5 94
FLU 5.5 80 15.2 84
FLU-OH 6.6 67 13.6 94
OXI 6.2 71 12.9 98
a The analyte concentration of inhibitor (analyte) required to reduce the response to by 50%
in HBS-EP buffer
bCross-reactivity of antibody to test benzimidazole at 50% inhibition ((IC50 ABZ-SO / IC50
test BZT) x 100) in HBS-EP buffer.
c The analyte concentration of inhibitor (analyte) required to reduce the response to by 50%
in bovine milk
dCross-reactivity of antibody to test benzimidazole at 50% inhibition ((IC50 ABZ-SO / IC50
test BZT) x 100) in bovine milk
7. Table 4
Table 4 Determination of assay detection capability (CCβ): The concentration of
benzimidazole residues determined by biosensor analysis of milk fortified at 5 µg kg-1
with 11 benzimidazole marker residues (n=20).
Analyte
Mean ± s
(μg kg-1) Minimum (μg kg
-1) Maximum (μg kg-1) CCβ (μg kg-1)
ABZ 5.39 ± 0.87 3.65 6.84 <5.00
ABZ-SO 3.83 ± 0.64 2.90 5.50 <5.00
ABZ-SO2 5.73 ± 1.68 3.39 10.00 <5.00
FBZ 5.15 ±1.56 3.48 8.54 <5.00
FBZ-SO2 8.93 ± 0.80 7.84 11.10 <5.00
FLU 9.37 ± 2.00 4.90 11.80 <5.00
FLU-OH 3.78 ± 0.76 2.65 5.43 5.00
MBZ 4.06 ± 1.21 2.03 7.01 5.00
MBZ-OH 4.49 ± 1.23 3.00 7.78 <5.00
FBZ-SO 4.45 ± 0.97 3.00 6.08 <5.00
OXI 4.86 ± 2.26 2.76 10.10 <5.00
7. Table 5
Table 5 Biosensor assay repeatability study: Recovery of 11 benzimidazole marker
residues from milk fortified at 5 µg kg-1 on five different days.
Analyte
Mean Recovery (%)
± S (n=5)
CV (%)
(n=5)
ABZ 97±34 35
ABZ-SO 111± 27 25
ABZ-SO2 116 ± 16 13
FBZ 81 ± 16 20
FBZ-SO2 107 ± 25 23
FLU 111± 37 33
FLU-OH 85 ± 10 11
MBZ 93 ± 25 27
MBZ-OH 81± 22 27
FBZ-SO 101 ± 30 29
OXI 96 ± 25 26
7. Table 6
Table 6 Comparison between biosensor and UPLC-MS/MS analysis of milk samples
from cows treated with FBZ and febantel.
Biosensor assay UPLC-MS/MS
Sample Withdrawal
time (h)
MRL
(jig
kg-')
Concentration Interpretation
(jig kg-')
(LOD = 2.7
jig kg-')
'Concentration
(jig kg-')
2Status
Dairy cow treated at 7.5 mg kg-1 b.w. (FBZ)
1 0 10 ND Negative ND C
2 15 10 >50 Positive 258.9 NC
3 24 10 >50 Positive 263.3 NC
4 39 10 >50 Positive 171.3 NC
5 48 10 >50 Positive 74.2 NC
6 63 10 20.0 Positive 7.5 C
7 72 10 5.7 Positive 2.5 C
8 87 10 ND Negative ND C
9 96 10 ND Negative ND C
10 111 10 ND Negative ND C
11 120 10 ND Negative ND C
12 135 10 ND Negative ND
Dairy cow treated at 5 mg kg-1 b.w. (febantel)
C
13 7 10 >50 Positive 250.5 NC
14 24 10 >50 Positive 336.3 NC
15 31 10 >50 Positive 219.3 NC
16 168 10 ND Negative ND C
1UPLC-MS/MS concentrations are expressed as the sum of FBZ, FBZ-SO and FBZ-
SO2 residues expressed as FBZ-SO2).
2C = compliant and NC = non-compliant
7. Table 7
Table 7 Comparison between biosensor and UPLC-MS/MS analysis of milk samples
from a cow treated with albendazole.
Biosensor assay UPLC-MS/MS
Sample Withdrawal MRL Concentration
time (h) (jig (jig kg-')
kg-')
Interpretation
(LOD =2.7
jig kg - ')
'Concentration
(jig kg-')
2Status
Dairy cow treated at 7.5 mg kg-1 b.w. (albendazole)
1 0 100 ND Negative ND C
2 15 100 >50 Positive 507.6 NC
3 24 100 >50 Positive 94.2 C
4 39 100 33.9 Positive 56.1 C
5 48 100 11.9 Positive 38.0 C
6 63 100 4.3 Positive 16.7 C
7 72 100 ND Negative 10.5 C
8 87 100 ND Negative 2.3 C
9 96 100 ND Negative ND C
10 111 100 ND Negative ND C
11 120 100 ND Negative ND C
12 135 100 ND Negative ND C
1UPLC-MS/MS concentrations are expressed as the sum of ABZ, ABZ-SO, ABZ-SO2
and ABZ-NH2-SO2 residues expressed as ABZ.
2C =
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Fig. 4b LC-MS/MS chromatograms of ABZ, ABZ-SO, ABZ-SO2and ABZ-NH2-SO2
residues detected in milk sample from Endospec 10% study (15 h withdrawal)
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